{
"id":"mk19_b_rm_t11",
"number":11,
"bookId":"rm",
"title":{
"__html":"Other Biologic Disease-Modifying Antirheumatic Drugs<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"34b7bd",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 11. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t11"
}
]
},
"Other Biologic Disease-Modifying Antirheumatic Drugs",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"744605",
"class":"col hd l",
"children":[
"Agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"27b1db",
"class":"col hd l",
"children":[
"Agent Structure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c41a31",
"class":"col hd l",
"children":[
"Target"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b670b8",
"class":"col hd l",
"children":[
"Indications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"42b72b",
"class":"cell txt l",
"children":[
"Abatacept"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bef53a",
"class":"cell txt l",
"children":[
"Soluble CTLA4 receptor/IgG Fc segment chimera"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1d812f",
"class":"cell txt l",
"children":[
"CD80/CD86; blocks T-cell costimulation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"36fb81",
"class":"cell txt l",
"children":[
"RA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"afd128",
"class":"cell txt l",
"children":[
"Preferred for patients with history of severe infection; relatively contraindicated in COPD"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fad6a2",
"class":"cell txt l",
"children":[
"Rituximab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"481595",
"class":"cell txt l",
"children":[
"Chimeric (mouse-human) monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f9f8c",
"class":"cell txt l",
"children":[
"CD20",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"+"
]
},
" B cells"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe9dc1",
"class":"cell txt l",
"children":[
"RA; ANCA-associated vasculitis; occasionally for SLE (off-label); IgG4-related disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a308f",
"class":"cell txt l",
"children":[
"Given as intravenous infusion over several hours; has higher risk for infusion reactions than other biologic DMARDs; can cause hypogammaglobulinemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2aee23",
"class":"cell txt l",
"children":[
"Tocilizumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e2f9a",
"class":"cell txt l",
"children":[
"Humanized monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ffe30",
"class":"cell txt l",
"children":[
"IL-6 receptor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0be2c9",
"class":"cell txt l",
"children":[
"RA; JIA; Castleman disease; GCA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"30c8c6",
"class":"cell txt l",
"children":[
"Can cause elevated aminotransferase levels, hyperlipidemia, leukopenia, thrombocytopenia; avoid in patients with history of diverticulitis because of attendant risk for bowel perforation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"40a580",
"class":"cell txt l",
"children":[
"Sarilumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa90a5",
"class":"cell txt l",
"children":[
"Human monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ffe30",
"class":"cell txt l",
"children":[
"IL-6 receptor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"36fb81",
"class":"cell txt l",
"children":[
"RA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6daeef",
"class":"cell txt l",
"children":[
"Can cause elevated aminotransferase levels, hyperlipidemia, leukopenia, thrombocytopenia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e24cc5",
"class":"cell txt l",
"children":[
"Belimumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa90a5",
"class":"cell txt l",
"children":[
"Human monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c242eb",
"class":"cell txt l",
"children":[
"BLyS/BAFF"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64e67e",
"class":"cell txt l",
"children":[
"SLE; lupus nephritis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31cf0a",
"class":"cell txt l",
"children":[
"Phase III trials showed small but statistically significant improvement versus standard therapy alone, with glucocorticoid-sparing effect"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d8182",
"class":"cell txt l",
"children":[
"Ustekinumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa90a5",
"class":"cell txt l",
"children":[
"Human monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ba4c44",
"class":"cell txt l",
"children":[
"IL-12/IL-23"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"830d77",
"class":"cell txt l",
"children":[
"Psoriasis; psoriatic arthritis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0cbc65",
"class":"cell txt l",
"children":[
"Injectable; less robust effect than other biologic DMARDs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e3b6ad",
"class":"cell txt l",
"children":[
"Secukinumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa90a5",
"class":"cell txt l",
"children":[
"Human monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d62f88",
"class":"cell txt l",
"children":[
"IL-17a"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"503c9f",
"class":"cell txt l",
"children":[
"Psoriatic arthritis; ankylosing spondylitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9cbbbc",
"class":"cell txt l",
"children":[
"Phase III trials suggest efficacy equal to that of TNF inhibitors; can cause IBD flares"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c44ef3",
"class":"cell txt l",
"children":[
"Ixekizumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e2f9a",
"class":"cell txt l",
"children":[
"Humanized monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d62f88",
"class":"cell txt l",
"children":[
"IL-17a"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"503c9f",
"class":"cell txt l",
"children":[
"Psoriatic arthritis; ankylosing spondylitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9cbbbc",
"class":"cell txt l",
"children":[
"Phase III trials suggest efficacy equal to that of TNF inhibitors; can cause IBD flares"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de978f",
"class":"cell txt l",
"children":[
"Guselkumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa90a5",
"class":"cell txt l",
"children":[
"Human monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c6e56e",
"class":"cell txt l",
"children":[
"IL-23"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"830d77",
"class":"cell txt l",
"children":[
"Psoriasis; psoriatic arthritis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6d6b42",
"class":"cell txt l",
"children":[
"Selective IL-23 inhibitor"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c82074",
"class":"cell txt l",
"children":[
"Anakinra"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4f3bb",
"class":"cell txt l",
"children":[
"Recombinant receptor antagonist"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ee6a00",
"class":"cell txt l",
"children":[
"IL-1β receptor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1c9495",
"class":"cell txt l",
"children":[
"RA; CAPS",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"; AOSD (off-label); acute gouty arthritis (off-label)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f432f8",
"class":"cell txt l",
"children":[
"Rarely used in RA because efficacy is inferior to that of other biologic DMARDs; reversible neutropenia can develop"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ecd2af",
"class":"cell txt l",
"children":[
"Canakinumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa90a5",
"class":"cell txt l",
"children":[
"Human monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b723d9",
"class":"cell txt l",
"children":[
"IL-1β"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7d617c",
"class":"cell txt l",
"children":[
"CAPS",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"767a1d",
"class":"cell txt l",
"children":[
"More expensive IL-1β inhibitor"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-12 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7df1c5",
"class":"cell txt l",
"children":[
"Rilonacept"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"543ea7",
"class":"cell txt l",
"children":[
"Dual IL-1β receptors chimerically attached to IgG Fc segment"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a71551",
"class":"cell txt l",
"children":[
"IL-1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a06e9",
"class":"cell txt l",
"children":[
"CAPS",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"; refractory gout"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1ded8",
"class":"cell txt l",
"children":[
"More expensive IL-1 inhibitor"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-13 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b450a0",
"class":"cell txt l",
"children":[
"Mepolizumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e2f9a",
"class":"cell txt l",
"children":[
"Humanized monoclonal antibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da1085",
"class":"cell txt l",
"children":[
"IL-5"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f7c9a",
"class":"cell txt l",
"children":[
"EGPA; eosinophilic asthma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cb0ba9",
"class":"cell txt l",
"children":[
"Only biologic approved for treatment of EGPA"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"AOSD = adult-onset Still disease; BAFF = B-cell–activating factor; BLyS = B-lymphocyte stimulator; CAPS = cryopyrin-associated periodic syndromes; DMARD = disease-modifying antirheumatic drug; EGPA = eosinophilic granulomatosis with polyangiitis; GCA = giant cell arteritis; IBD = inflammatory bowel disease; IL = interleukin; JIA = juvenile idiopathic arthritis; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; TNF = tumor necrosis factor."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Before initiation of any biologic, tuberculosis screening must be performed. Complete blood counts should be performed every 3 to 6 months for all biologics, and aspartate aminotransferase/alanine aminotransferase and a lipid panel should be checked every 2 to 3 months for tocilizumab."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"The cryopyrin-associated periodic syndromes (CAPS) include familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (chronic infantile neurologic, cutaneous, articular syndrome)."
]
]
}